#igg4-related disease

1 story

#biotech #cash burn #clinical pipeline #fda approval #going concern #obexelimab #phase 3 trial #royalty pharma #zbio #zenas biopharma

Can Zenas BioPharma justify its $108M quarterly burn?
A clinical-stage biotech with $673.9M in cash races toward an FDA decision that will make or break its future.
Alphastreet - Earnings Decoded. Market Intelligence Delivered · 2m